



AGM OVERVIEW 2017

Prescient Therapeutics Limited (ASX: PTX)
20 November 2017

DISCLAIMER AND SAFE HARBOR

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited (“Prescient” or the “Company”), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words ‘estimate’, ‘project’, ‘intend’, ‘expect’, ‘plan’, ‘believe’, ‘guidance’, and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management’s current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.


INVESTMENT HIGHLIGHTS

2 DRUGS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE

- **2 targeted therapies** with impeccable scientific pedigree
- Multiple shots on goal with **Akt and Ras pathway inhibitors** in **multiple trials**
- **One of deepest clinical pipelines on the ASX**
 - » Targeting important areas of unmet clinical need
- **Multiple catalysts** for value creation
- **Funded through to value-accretive catalysts**, with a fantastic share register
- Phase 1b/2 AML trial is being led by globally renowned leukaemia expert, Professor Jeff Lancet
 - » Professor Lancet also led Celator Pharmaceuticals' ground-breaking VYXEOS trial in AML
- Great scientific and clinical team with a **proven record of success**
- Recent **encouraging breast cancer results, despite SAE resulting in clinical hold**
- **Transformative opportunity in rare blood (haem) cancers**


DEEP, CLINICAL STAGE PRODUCT PIPELINE

- PTX-200 currently in three clinical trials (BRCA recruitment currently on hold pending SAE response)
- Advancing PTX-100 in rare haematological cancers – a transformative opportunity



HOW OUR DRUGS WORK: A REFRESH


Akt & Ras are growth molecules found in cells – when they are stuck “on”, they send **constant signals to the cancer cell to grow**



PTX's drugs block the Akt & Ras growth pathways, switching the growth signals off and **causing the cancer cell to die**



INVESTMENT DECISION FUNNEL FOR ANY BIOTECH



LAST YEAR WE SAID

- AML trial currently screening for first patient Ph1b ✓
- Ovarian cancer currently screening next patient Ph1b ✓
- Breast Cancer Ph1b expansion cohort nearing completion ✓
- Manufacturing new batch of PTX-200 ✓
- Interest in PTX-100 – planning development program ✓
- Building awareness of company and our programs ahead of data ✓

THE YEAR IN REVIEW

- Manufacturing run of PTX-200
- Commencement of PTX-200 Phase 1b AML trial
- Successful completion of Phase 1b PTX-200 breast cancer trial
- Subsequent SAE on patient on breast cancer trial leading to clinical hold on all PTX-200 trials
- Progression of Phase 1b/2 PTX-200 ovarian cancer trial, with first cohort completed
- Granting of three additional US patents and a European patent for PTX-200
- Granting of Orphan Drug Designation for PTX-200 by U.S. FDA
- PTX-100 pre-clinical study published in prestigious scientific journal *Nature*
- Lifting of clinical hold on PTX-200 trials in AML and ovarian cancer
- Strategic review of indications for PYTX-100 and identification of a truly transformative opportunity in RhoA mutant lymphomas
- Identification of Patent application for PTX-100 in RhoA mutant cancers
- Appointment of new highly-experienced individuals to the team
- Built global awareness of company and our programs

THE PTX-200 CLINICAL HOLD

- After completion of the Phase 1b breast cancer trial, last patient passed away from liver failure
- Hold on all 3 PTX-200 programs
- Share price dropped 30%
- Review on all data in PTX-200 trials
- Enhanced safety measures include:
 - » Excluding patients with liver disease
 - » More frequent liver function tests
- Hold lifted on AML trial Sept
- Hold lifted on ovarian cancer trial November
- Share price still recovering but trending in right direction


BIG OPPORTUNITY IN RARE HEMATOLOGICAL NICHE

- Recent discovery that RhoA mutations are a key driver in certain haematological cancers
- Some of these conditions are characterized **high unmet need**:
 - » Rare
 - » Poor prognoses with short median survival
 - » Very few existing treatment options
 - » Very few drugs in development
- **PTX-100 is uniquely positioned to address this unmet need due to its mechanism of action**
- Prescient recently lodged new patent application in this area.
- Case study : Folutyn (Spectrum Pharmaceuticals)
 - » For relapsed & refractory Peripheral T-cell lymphoma
 - » 5,600 cases/year in US
 - » Approved on overall response rate of 27%
 - » Currently priced at US\$450,540 per year



RAS PATHWAY, AND RHOA IN PARTICULAR, ARE IMPLICATED IN A NUMBER OF HEMATOLOGICAL MALIGNANCIES


Frequency of RhoA mutations in human malignancies



nature
genetics




Experimental
Hematology




- In addition, **N-Ras** and **K-Ras** contribute to several heme malignancies including:
 - » Acute Myeloid Leukemia (AML)
 - » Chronic Myelomonocytic Leukemia (CMML)
 - » Juvenile Myelomonocytic Leukemia (JMML)
 - » Multiple Myeloma (MM)
 - » Ras-associated Autoimmune Leukoproliferative Disorder (RALD)

PTX-100 THE MOST ADVANCED DRUG TARGETING RHOA



- Only 12 RhoA inhibitors in development in oncology
 - » No others are in the clinic
 - » None are in hematology indications
 - » PTX-100 is the most advanced, with Phase 1 trial in solid tumours completed
- **PTX-100 has a head start and unique position in RhoA mutant lymphomas**



WHEN TARGET THERAPIES MEET RARE DISEASES

Bayer agrees cancer drug deal with Loxo worth up to \$1.55 bln

November 14, 2017, 10:08:00 AM EDT By Reuters


- Loxo Oncology (NASDAQ: LOXO); \$2.3B market cap
- TRK inhibitor targeting cancers with TRK fusions
- Deal for LOXO-101 and LOXO-195
- In mid-stage clinical trials. ORR 75%
- US\$400m upfront
- Loxo could earn up to US\$1.55 Billion
- Bayer and Loxo co-promote in US; Bayer solo RoW



Loxo Oncology Inc
NASDAQ: LOXO - 15 Nov., 4:00 pm GMT-5

76.04 USD ↓0.00 (0.00%)

1 day 5 day 1 month 3 months 1 year 5 years max



WHEN TARGET THERAPIES MEET RARE DISEASES

- Blueprint Medicines (NASDAQ: BPMC)
- Target therapies for cancer based on genomically defined diseases (abnormal kinase activation)
- 4x Phase 1 drugs
- 3 x discovery programs
- IPO April 2015: Valuation: US\$398M; \$16/share
- Today: Valuation: US\$2.5 B; \$64/share



Blueprint Medicines Corp
NASDAQ: BPMC - 15 Nov., 5:28 pm GMT-5

64.29 USD ▲0.37 (0.58%)
After-hours: 64.29 0.00 (0.00%)



WHEN TARGET THERAPIES MEET RARE DISEASES

- Prescient Therapeutics (ASX: PTX); market cap \$14M
- Target therapies for cancer
- Hyper pAkt – PTX-200
 - » Orphan drug designation in AML
- Ras pathway mutations – PTX-100
 - » Ultra-orphan RhoA mutant lymphomas
- **A step behind some US peers, but treading the same path**



IN THE NEXT 12 MONTHS WE WILL WORK TOWARDS:

- Removal of clinical hold on PTX-200 breast cancer trial
- Final data on the Phase 1b PTX-200 breast cancer trial
- Manufacturing run of PTX-100 and additional inventory of PTX-200
- Pre-clinical work in PTX-100 in RhoA mutant cancers
- Completion of PTX-200 AML Phase 1b trial
- Completion of PTX-200 Ovarian cancer Phase 1b trial
- Re-entering the clinic with PTX-100 in haematological malignancies
- Continuing to build awareness among investors, clinicians and corporates

THANK YOU

...Thank you to our shareholders for their ongoing support

...Thank you to our Board, staff and clinical faculty for working successfully through the challenges this year

...Thank you to the brave patients we treat, and their families and support networks

Together we are all helping develop much needed new therapies to patients who are often on their last chance



THANK YOU

CONTACT

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited

e: steven@ptxtherapeutics.com
t: +61 417 601 440
w: ptxtherapeutics.com